Singapore, Aug. 26 -- Japan's Meiji Seika Pharma has announced that its local subsidiary, Thai Meiji Pharmaceutical has received regulatory approval from the Food and Drug Administration, the Ministry of Public Health in Thailand for REZUROCK(R) (product name in Thailand, INN: belumosudil), a selective rho-associated, coiled-coil containing protein kinase 2 (ROCK2) inhibitor for the treatment of chronic graft-versus-host disease (chronic GVHD).

REZUROCK(R) will be marketed by Thai Meiji Pharmaceutical on behalf of Romeck Pharma LLC, the joint venture between Meiji Seika Pharma and Kadmon Corporation LLC, a Sanofi group company.

Published by HT Digital Content Services with permission from BioSpectrum Asia....